Non-small cell lung cancer in the elderly - Systemic therapy

Cancer Forum

Volumn 32, Issue 1, 2008, Pages 16-19

  Cheong, Kerry ^a  

^a Adelaide Cancer Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DRUG CLEARANCE; ELDERLY CARE; EYE IRRITATION; FEBRILE NEUTROPENIA; FIBROSING ALVEOLITIS; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; NEUROTOXICITY; OTOTOXICITY; PSYCHOPATHY; QUALITY OF LIFE; RASH;

EID: 42149176566     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Cheong KA, Chrystal K, Harper PG. Management of the elderly patient with advanced non-small cell lung cancer. Int J Clin Pract. 2006 Mar; 60(3): 340-3.
2. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer. 2003 Sep; 41(3):245-58.
3. de Rijke JM, Schouten LJ, ten Velde GP et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004 Nov; 46(2):233-45.
4. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000 May; 117(5):1239-46.
5. Peake MD, Thompson S, Lowe D, et al. Ageism in the management of lung cancer. Age Ageing. 2003 Mar; 32(2):171-7.
6. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol. 2007 May 10;25(14):1898-907.
7. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224-37.
8. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007 May 10;25(14):1824-31.
9. Maione P, Perrone F, Gallo C, et al. Pre-treatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005 Oct 1;23(28):6865-72.
10. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002 Jan 15;20(2):494-502.
11. LeCaer H, Fournel P Jullian H, et al. An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study. Crit Rev Oncol Hematol. 2007 Oct;64(1):73-81.
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.
13. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57.
14. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst, 1999 Jan 6; 91(1): p. 66-72.
15. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72.
16. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006 Aug 1; 24(22):3657-63.
17. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002 Feb 6; 94(3):173-81.
18. Langer C, Vangel M, Schiller J, et al. Age-specific sub-analysis of ECOG 1594: Fit elderly patients (70-80 yrs) do as well as younger pts (<70).Proc Am Soc Clin Oncol. 2003. Chicago.
19. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005 May 1; 23(13):3125-37.
20. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000 Aug; 83(4):447-53.
21. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007 Oct 10;25(29):4663-9.
22. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer. 2007 Aug 27.
23. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
24. Breen D, Barlesi F, Zemerli M, et al. Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged >80 years. Clin Lung Cancer. 2007 Mar; 8(5):331-4.
25. Shepherd FA, Rodrigues, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14; 353(2):123-32.
26. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 1; 25(7):760-6
27. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004 Mar 1; 22(5):785-94.
28. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004 Mar 1; 22(5):777-84.
29. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1; 23(25):5892-9.
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007 Apr 20; 25(12):1545-52.
31. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14; 355(24):2542-50.
32. Manegold C, Von Pawel J, Zatloukal P, et al. Randomized, double blind, multicentre phase 3 study of bevacizumab in combination with cisplatin and gemcitabine in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer: BO17704. Proc Am Soc Clin Oncol. 2007. Chicago.
33. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007 Apr 20; 25(12):1553-61.
34. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23; 352(25):2589-97.